Ultragenyx Pharmaceutical reported $96.44M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Insmed USD 212.58M 210.76M Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Kyowa Hakko Kirin JPY 523.49M 0 Sep/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025